Status:
COMPLETED
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborating Sponsors:
United States Department of Defense
Molecular NeuroImaging
Conditions:
Parkinson Disease
Parkinsonian Syndrome
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by rigidity, bradykinesia, postural instability, and tremor. Clinical decline reflects ongoing degeneration of dopami...
Detailed Description
Individuals who agree to participate in this trial will have a complete screening exam by a neurologist at the Institute for Neurodegenerative Disorders (IND) in New Haven, CT. The exam may include bl...
Eligibility Criteria
Inclusion
- Age \>21
- Previous participation in the Progeni or Core PD clinical study
- A diagnosis of parkinsonism or a family history of parkinsonism
- Normal screening laboratory studies including:
- complete blood count
- chemistries
- urinalysis
Exclusion
- Pregnancy
- Psychiatric disease other than history of depression
- Significant medical disease including abnormalities on screening biochemical or hematological labs or abnormal ECG.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00273351
Start Date
January 1 2006
End Date
January 1 2008
Last Update
May 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510